GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Short Percentage of Float

Syndax Pharmaceuticals (STU:1T3) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Syndax Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Syndax Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Short Percentage of Float falls into.


;
;

Syndax Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Short Percentage of Float
Comparable Companies
AUPH INVA ADPT NVAX MDXG IOVA ARDX VRDN ETNB SYRE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
SNDX:USA
Address
730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Website
https://www.syndax.com
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines